Search / Trial NCT06229964

Frozen Shoulder Treatment With Intra-Articular Corticosteroid Injection and Suprascapular Nerve Block

Launched by UNIVERSITAIR ZIEKENHUIS BRUSSEL · Jan 25, 2024

Trial Information

Current as of December 21, 2024

Not yet recruiting

Keywords

Frozen Shoulder Adhesive Capsulitis Of The Shoulder Intra Articular Corticosteroid Injection Ultra Sound Guided Injection Suprascapular Nerve Block Joint Diseases Musculoskeletal Diseases Bursitis

ClinConnect Summary

Frozen Shoulder (FS) is common disease affecting 2 to 5% of the general population, with a higher prevalence in patients suffering from diabetes and thyroid dysfunction.It remains frustrating for patients and treating health care professionals as severe shoulder pain and loss of function can last for up to two years. 5-7 In the early stage, most patients identify the following symptoms: strong component of night pain, pain with rapid or unguarded movements and aggravated by movement or lying on the affected shoulder.8 Combined with marked pain and limitation in all directions of shoulder ra...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Written informed consent to participate in the study must be obtained from the subject prior to initiation of any study-mandated procedure
  • Suffering from Frozen Shoulder, defined as: Frozen shoulder is a self-limiting disease characterized by pain and functional restriction in both active and passive shoulder motion lasting more than 1 month, for which radiographic findings of the shoulder joint are unremarkable.
  • Dutch or French speaking persons
  • Age ≥ 18 years
  • Exclusion Criteria:
  • Subjects with posttraumatic or postsurgical stiff shoulder syndrome
  • History of trauma at the onset of symptoms
  • Subjects with rheumatologic or neurologic disease involving the shoulder
  • Subjects with cervical radiculopathy
  • Coagulation disorder
  • Hypersensitivity to local anesthetics or MRI contrast agent
  • Inability to understand the study procedures
  • Psychiatric illness
  • Pregnancy
  • Subjects who have received prior SSNB in the homolateral shoulder
  • Subjects who have received an IACI in the homolateral shoulder in the 3 months before inclusion

Trial Officials

Marc Schiltz, MD

Principal Investigator

Universitair Ziekenhuis Brussel

About Universitair Ziekenhuis Brussel

Universitair Ziekenhuis Brussel (UZ Brussel) is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent institution affiliated with the Vrije Universiteit Brussel, UZ Brussel integrates cutting-edge medical research with high-quality patient care. The hospital's multidisciplinary teams are dedicated to exploring novel therapeutic approaches and contributing to the development of evidence-based treatments, ensuring the highest standards of safety and efficacy in clinical research. With a strong focus on collaboration and knowledge dissemination, UZ Brussel plays a pivotal role in shaping the future of medicine and improving patient outcomes.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0